Published in Blood on December 17, 2007
Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J (2008) 1.19
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood (2010) 1.08
Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res (2010) 0.97
Long-lived bone marrow plasma cells are induced early in response to T cell-independent or T cell-dependent antigens. J Immunol (2012) 0.97
Short- and long-term changes in gene expression mediated by the activation of TLR9. Mol Immunol (2009) 0.95
Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells. J Immunol (2011) 0.93
Toll-like receptor 9 is required for opioid-induced microglia apoptosis. PLoS One (2011) 0.90
Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation. Genes Dis (2014) 0.90
Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest (2015) 0.89
Controlled DNA double-strand break induction in mice reveals post-damage transcriptome stability. Nucleic Acids Res (2015) 0.80
Effects of Toll-like receptor signals in T-cell neoplasms. Future Oncol (2011) 0.79
Immunomodulation by gut microbiota: role of Toll-like receptor expressed by T cells. J Immunol Res (2014) 0.78
A "Toll" for Th17 cell expansion. J Leukoc Biol (2010) 0.77
Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation. Mol Cells (2015) 0.77
Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis. Immunology (2016) 0.75
Close Encounters of Lymphoid Cells and Bacteria. Front Immunol (2016) 0.75
Pattern recognition receptors and DNA repair: starting to put a jigsaw puzzle together. Front Immunol (2014) 0.75
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature (2003) 20.13
Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 19.15
The DNA damage response: putting checkpoints in perspective. Nature (2000) 19.07
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev (2001) 12.46
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science (1998) 8.74
Regulation of RAD53 by the ATM-like kinases MEC1 and TEL1 in yeast cell cycle checkpoint pathways. Science (1996) 8.71
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res (1999) 7.82
BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev (2000) 7.29
ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol (2001) 7.26
The many substrates and functions of ATM. Nat Rev Mol Cell Biol (2000) 5.46
Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett (2003) 5.27
Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med (2003) 4.96
Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res (1998) 4.52
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 4.32
Cancer immunotherapy: a treatment for the masses. Science (2004) 4.04
The comet assay: a comprehensive review. Mutat Res (1995) 3.80
Caspase function in programmed cell death. Cell Death Differ (2006) 3.77
Improving T cell therapy for cancer. Annu Rev Immunol (2007) 3.10
TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A (2004) 3.04
Toll-like receptor ligands directly promote activated CD4+ T cell survival. J Immunol (2004) 2.79
Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-gamma production by memory CD4+ T cells. J Immunol (2005) 2.67
The mismatch repair system is required for S-phase checkpoint activation. Nat Genet (2002) 2.55
Regulation of lymphocyte survival by the bcl-2 gene family. Annu Rev Immunol (1995) 2.48
Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages. Eur J Immunol (2003) 2.47
BCL2 family in DNA damage and cell cycle control. Cell Death Differ (2006) 2.42
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst (1996) 2.39
Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys (2005) 2.29
Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci U S A (1996) 2.19
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res (2005) 1.97
Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci (2004) 1.95
MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. Proc Natl Acad Sci U S A (2003) 1.90
Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene (2001) 1.83
TLR2 engagement on CD8 T cells lowers the threshold for optimal antigen-induced T cell activation. Eur J Immunol (2006) 1.79
Radioprotectors in radiotherapy. J Radiat Res (2001) 1.74
Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia (2006) 1.63
Bcl-xL/Bcl-2 coordinately regulates apoptosis, cell cycle arrest and cell cycle entry. EMBO J (2003) 1.59
Retracted DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell (2000) 1.49
The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation. J Biol Chem (2001) 1.48
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis (2006) 1.47
CpG-oligodeoxynucleotides co-stimulate primary T cells in the absence of antigen-presenting cells. Eur J Immunol (1999) 1.46
CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res (2003) 1.45
Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol (2000) 1.36
Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes. Blood (2000) 1.34
CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol (1998) 1.34
Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res (2003) 1.32
Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem (2001) 1.27
Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. Oncogene (1997) 1.25
CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res (2004) 1.25
CpG DNA activates survival in murine macrophages through TLR9 and the phosphatidylinositol 3-kinase-Akt pathway. J Immunol (2006) 1.21
Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell (2005) 1.19
Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int J Cancer (2005) 1.18
CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol (1996) 1.18
Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. Int Immunol (2003) 1.14
CpG motifs in bacterial DNA delay apoptosis of neutrophil granulocytes. FASEB J (2004) 1.12
CpG oligodeoxynucleotides are potent enhancers of radio- and chemoresponses of murine tumors. Radiother Oncol (2006) 1.07
Recent patterns of growth in radiation therapy facilities in the United States: a patterns of care study report. Int J Radiat Oncol Biol Phys (1992) 1.06
Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. Oncogene (1996) 1.05
TLR9 ligand enhances proliferation of rat CD4+ T cell and modulates suppressive activity mediated by CD4+ CD25+ T cell. Int Immunol (2007) 0.99
Bacterial lipoprotein delays apoptosis in human neutrophils through inhibition of caspase-3 activity: regulatory roles for CD14 and TLR-2. J Immunol (2004) 0.98
UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun (1996) 0.97
Resisting arrest: recovery from checkpoint arrest through dephosphorylation of Chk1 by PP1. Cell Cycle (2004) 0.96
Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment. Blood (2002) 0.95
Current developments of immunotherapy in the clinic. Curr Opin Immunol (2004) 0.94
Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol Cancer Ther (2006) 0.93
CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int Immunol (1999) 0.90
CpG-B oligodeoxynucleotide promotes cell survival via up-regulation of Hsp70 to increase Bcl-xL and to decrease apoptosis-inducing factor translocation. J Biol Chem (2006) 0.87
CpG-oligodeoxynucleotide protects immune cells from gamma-irradiation-induced cell death. Mol Immunol (2005) 0.82
Cytotoxic drugs and the granulopoietic system. Recent Results Cancer Res (1982) 0.82
A practical synthesis of (Z)-debromohymenialdisine. J Org Chem (2000) 0.78
Simultaneous assay by six methods of the effect on haemopoietic precursor cells of adriamycin, methyl CCNU, 60Co gamma-rays, vinblastine, and cytosine arabinoside. Exp Hematol (1978) 0.78
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res (2009) 2.90
DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol (2007) 2.47
Sonic hedgehog is an autocrine viability factor for myofibroblastic hepatic stellate cells. J Hepatol (2007) 2.16
Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. J Biol Chem (2004) 1.88
Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans. Gastroenterology (2008) 1.71
Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis (2006) 1.47
Epigenetic silencing of the tumor suppressor cystatin M occurs during breast cancer progression. Cancer Res (2006) 1.20
Methylator-induced, mismatch repair-dependent G2 arrest is activated through Chk1 and Chk2. Mol Biol Cell (2005) 1.19
Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity. FASEB J (2008) 1.19
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation (2008) 1.17
The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis (2008) 1.17
The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene (2004) 1.16
DNMT1 knockout delivers a strong blow to genome stability and cell viability. Nat Genet (2007) 1.12
Distance communication transfer of HIV prevention interventions to service providers. Science (2004) 1.12
Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway. Blood (2011) 1.10
When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function. Blood (2010) 1.08
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood (2005) 1.08
Comparative epigenomics of human and mouse mammary tumors. Genes Chromosomes Cancer (2009) 1.07
Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colorectal tumor cell line. Oncogene (2002) 1.07
Identification of quantitative trait Loci that affect aggressive behavior in mice. J Neurosci (2002) 1.07
ATM is activated in response to N-methyl-N'-nitro-N-nitrosoguanidine-induced DNA alkylation. J Biol Chem (2002) 1.06
Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest (2008) 1.06
The ATM gene is a target for epigenetic silencing in locally advanced breast cancer. Oncogene (2004) 1.06
Rapid and transient recruitment of DNMT1 to DNA double-strand breaks is mediated by its interaction with multiple components of the DNA damage response machinery. Hum Mol Genet (2010) 1.06
The ATM-SMC1 pathway is essential for activation of the chromium[VI]-induced S-phase checkpoint. Mutat Res (2004) 1.06
Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther (2013) 1.05
Caspase-3 mediated cleavage of BRCA1 during UV-induced apoptosis. Oncogene (2002) 1.04
Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev (2004) 1.00
The monofunctional alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine triggers apoptosis through p53-dependent and -independent pathways. Toxicol Appl Pharmacol (2005) 0.99
HIV prevention in Africa: programs and populations served by non-governmental organizations. J Community Health (2004) 0.98
Mechanisms of TNF receptor-associated factor (TRAF) regulation in B lymphocytes. J Leukoc Biol (2002) 0.98
Amplifying TLR-MyD88 signals within tumor-specific T cells enhances antitumor activity to suboptimal levels of weakly immunogenic tumor antigens. Cancer Res (2010) 0.97
Citrulline can preserve proliferation and prevent the loss of CD3 zeta chain under conditions of low arginine. JPEN J Parenter Enteral Nutr (2004) 0.96
Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res (2012) 0.95
WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis (2011) 0.93
Cod glycopeptide with picomolar affinity to galectin-3 suppresses T-cell apoptosis and prostate cancer metastasis. Proc Natl Acad Sci U S A (2013) 0.92
Characterization of the novel amplified in breast cancer-1 (NABC1) gene product. Exp Cell Res (2003) 0.92
MLH1- and ATM-dependent MAPK signaling is activated through c-Abl in response to the alkylator N-methyl-N'-nitro-N'-nitrosoguanidine. J Biol Chem (2007) 0.92
Bisulfite sequencing of DNA. Curr Protoc Mol Biol (2010) 0.92
Augmentation of therapeutic responses in melanoma by inhibition of IRAK-1,-4. Cancer Res (2012) 0.90
Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies. J Clin Invest (2015) 0.89
DNA methyltransferase inhibitor, zebularine, delays tumor growth and induces apoptosis in a genetically engineered mouse model of breast cancer. Mol Cancer Ther (2011) 0.87
The transglutaminase 2 gene is aberrantly hypermethylated in glioma. J Neurooncol (2010) 0.87
Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression. J Biol Chem (2012) 0.87
The ATM/p53 pathway is commonly targeted for inactivation in squamous cell carcinoma of the head and neck (SCCHN) by multiple molecular mechanisms. Oral Oncol (2005) 0.86
A high throughput method for enrichment of natural killer cells and lymphocytes and assessment of in vitro cytotoxicity. J Immunol Methods (2013) 0.86
HIV prevention programs of nongovernmental organizations in Latin America and the Caribbean: the Global AIDS Intervention Network project. Rev Panam Salud Publica (2005) 0.85
Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol (2009) 0.85
The role of obesity in spontaneous temporal bone encephaloceles and CSF leak. Otol Neurotol (2012) 0.84
The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint. Mol Cancer Ther (2010) 0.83
A yoga-based exercise program to reduce the risk of falls in seniors: a pilot and feasibility study. J Altern Complement Med (2008) 0.81
Oxidative stress shapes breast cancer phenotype through chronic activation of ATM-dependent signaling. Breast Cancer Res Treat (2015) 0.81
N-methyl-N'-nitro-N-nitrosoguanidine activates cell-cycle arrest through distinct mechanisms activated in a dose-dependent manner. Mol Pharmacol (2005) 0.79
The Compound Action Potential in Subjects Receiving a Cochlear Implant. Otol Neurotol (2016) 0.79
Effects of Toll-like receptor signals in T-cell neoplasms. Future Oncol (2011) 0.79
Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. Cancer Res (2013) 0.79
Polycyclic aromatic hydrocarbons-induced ROS accumulation enhances mutagenic potential of T-antigen from human polyomavirus JC. J Cell Physiol (2013) 0.79
Exonuclease 1 (Exo1) is required for activating response to S(N)1 DNA methylating agents. DNA Repair (Amst) (2012) 0.79
Avoiding Tolerance Against Prostatic Antigens With Subdominant Peptide Epitopes. J Immunother (1991) (2001) 0.78
N-methyl-N'-nitro-N-nitrosoguanidine activates multiple cell death mechanisms in human fibroblasts. DNA Cell Biol (2007) 0.77
A "Toll" for Th17 cell expansion. J Leukoc Biol (2010) 0.77
Biology of T lymphocytes. Rheum Dis Clin North Am (2004) 0.76
The antimicrobial agent C31G is effective for therapy for HSV-1 ocular keratitis in the rabbit eye model. Antiviral Res (2013) 0.75
Frequency-to-Place Mismatch: Characterizing Variability and the Influence on Speech Perception Outcomes in Cochlear Implant Recipients. Ear Hear (1) 0.75
Prospective Evaluation of Patients Undergoing Translabyrinthine Excision of Vestibular Schwannoma with Concurrent Cochlear Implantation. Otol Neurotol (2017) 0.75
Cochlear Implantation in Cases of Unilateral Hearing Loss: Initial Localization Abilities. Ear Hear (2017) 0.75
Success of lateral graft technique for closure of tympanic membrane perforations. Otol Neurotol (2015) 0.75
A Case-Case Analysis of Intralabyrinthine Schwannoma Versus Intracanalicular Vestibular Schwannoma. Otol Neurotol (2022) 0.75
Factors Influencing Pediatric Cochlear Implant Outcomes: Carolina Sibling Study. Otol Neurotol (2019) 0.75
The use of KTP laser in revision stapedectomy. Otol Neurotol (2012) 0.75
Surveillance after resection of vestibular schwannoma: measurement techniques and predictors of growth. Otol Neurotol (2014) 0.75
Radiation-Induced Necrosis of the Temporal Bone: Diagnosis and Management. Otol Neurotol (2015) 0.75
Audiological Outcomes and Map Characteristics in Children With Perimodiolar and Slim Straight Array Cochlear Implants in Opposite Ears. Otol Neurotol (2017) 0.75